文献速递糖尿病

ELOVL2/DHA轴在糖脂毒性诱导的β细胞凋亡中的保护作用

Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets.
PubMed 文献 · Diabetologia · 2018-05-12

本研究探讨ELOVL2/DHA轴对棕榈酸联合高糖(糖脂毒性)诱导的β细胞凋亡的影响。在INS-1细胞、小鼠及人胰岛中,糖脂毒性降低ELOVL2含量,而下调ELOVL2加剧凋亡,过表达ELOVL2或补充DHA则部分抑制凋亡,该保护作用与减少神经酰胺积聚及促进棕榈酸氧化有关,且依赖CPT1。

要点

  • 糖脂毒性降低 rodent 和人β细胞中ELOVL2含量。
  • 下调ELOVL2加剧糖脂毒性诱导的β细胞凋亡,过表达ELOVL2或补充DHA部分抑制凋亡。
  • ELOVL2/DHA的抗凋亡作用与减少神经酰胺积聚及促进棕榈酸氧化相关。

核心结论

  • ELOVL2是防止糖脂毒性诱导β细胞死亡和功能障碍的关键促存活酶,主要通过CPT1依赖机制促进线粒体内棕榈酸氧化。

研究设计与样本

  • 在INS-1 β细胞、小鼠胰岛和人胰岛中检测ELOVL2表达,并进行ELOVL2下调和腺病毒过表达实验。
  • 使用放射性酶法和脂质组学测定神经酰胺和二酰甘油水平,通过caspase-3 assay和PARP cleavage定量凋亡。

主要发现

  • 糖脂毒性降低 rodent 和人β细胞中ELOVL2含量。
  • 下调ELOVL2显著加剧糖脂毒性诱导的β细胞凋亡,而过表达ELOVL2或补充DHA部分抑制 rodent 和人β细胞死亡。
  • ELOVL2/DHA轴抑制β细胞凋亡与神经酰胺积聚减少相关,但该轴不能直接改变神经酰胺合成或代谢。
  • DHA增加棕榈酸氧化但不影响其酯化。
  • 药理抑制AMPK或CPT1抑制剂etomoxir减弱ELOVL2/DHA的保护作用,下调CPT1也抵消其抗凋亡作用,而突变活性Cpt1在ELOVL2下调时抑制糖脂毒性诱导的β细胞凋亡。

临床怎么用

  • 原文未提及具体的临床转化建议,仅提示ELOVL2/DHA轴可能作为保护β细胞免受糖脂毒性损伤的潜在靶点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Dietary n-3 polyunsaturated fatty acids, especially docosahexaenoic acid (DHA), are known to influence glucose homeostasis. We recently showed that Elovl2 expression in beta cells, which regulates synthesis of endogenous DHA, was associated with glucose tolerance and played a key role in insulin secretion. The present study aimed to examine the role of the very long chain fatty acid elongase 2 (ELOVL2)/DHA axis on the adverse effects of palmitate with high glucose, a condition defined as glucolipotoxicity, on beta cells. METHODS: We detected ELOVL2 in INS-1 beta cells and mouse and human islets using quantitative PCR and western blotting. Downregulation and adenoviral overexpression of Elovl2 was carried out in beta cells. Ceramide and diacylglycerol levels were determined by radio-enzymatic assay and lipidomics. Apoptosis was quantified using caspase-3 assays and poly (ADP-ribose) polymerase cleavage. Palmitate oxidation and esterification were determined by [U-14C]palmitate labelling. RESULTS: We found that glucolipotoxicity decreased ELOVL2 content in rodent and human beta cells. Downregulation of ELOVL2 drastically potentiated beta cell apoptosis induced by glucolipotoxicity, whereas adenoviral Elovl2 overexpression and supplementation with DHA partially inhibited glucolipotoxicity-induced cell death in rodent and human beta cells. Inhibition of beta cell apoptosis by the ELOVL2/DHA axis was associated with a decrease in ceramide accumulation. However, the ELOVL2/DHA axis was unable to directly alter ceramide synthesis or metabolism. By contrast, DHA increased palmitate oxidation but did not affect its esterification. Pharmacological inhibition of AMP-activated protein kinase and etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in fatty acid β-oxidation, attenuated the protective effect of the ELOVL2/DHA axis during glucolipotoxicity. Downregulation of CPT1 also counteracted the anti-apoptotic action of the ELOVL2/DHA axis. By contrast, a mutated active form of Cpt1 inhibited glucolipotoxicity-induced beta cell apoptosis when ELOVL2 was downregulated. CONCLUSIONS/INTERPRETATION: Our results identify ELOVL2 as a critical pro-survival enzyme for preventing beta cell death and dysfunction induced by glucolipotoxicity, notably by favouring palmitate oxidation in mitochondria through a CPT1-dependent mechanism.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bellini L, Campana M, Rouch C, et al. Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets. Diabetologia. 2018. PMID: 29754287. doi:10.1007/s00125-018-4629-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。